All In Biotech

Drug Trial Radar · NCT07944092

Ph 1/2 Study to Evaluate Safety & Tolerability of FMC-242 Alone and in Combination in Adults With Advanced Solid Tumors

A Phase 1/2, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of FMC-242 as a Single Agent and in Combination in Participants With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

282

Planned (sponsor's estimate)

Start

Dec 2026

Primary completion

Jan 2029

Study completion Jan 2030

Sponsor

Lead sponsor
Frontier Medicines CorporationIndustry
Sponsor type
Industry
First posted
Nov 18, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn if treatment in adults with select solid tumors with FMC-242 alone and in combinations with other cancer drugs is safe and effective. The main questions it aims to answer are: Is treatment with FMC-242 alone safe and tolerable and at what dose? Is treatment with FMC-242 combined other cancer drugs safe and tolerable and at what doses? Participants will need to come to the clinic to have the following: * Physical exams to see if there are any side effects * Standard lab tests to observe blood counts and other values * ECGs to measure heart signals * Blood drawn to measure how the drugs are being metabolized * Imaging such as CT scans to monitor if the cancer is growing or not

Conditions

  • Locally Advanced Solid Tumor

Interventions

  • FMC-242Drug

    PI3Kα:RAS breaker

  • Trastuzumab (or biosimilar)Drug

    HER2 targeting agent

  • Fulvestrant (or generic)Drug

    selective estrogen receptor degrader

  • Pan (K)RAS inhibitorDrug

    Pan (K)RAS inhibitor

  • FMC-376Drug

    KRAS G12C inhibitor (experimental)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1 and Phase 2: Adverse EventsTime frame: Approximately 24 months
  2. Phase 1 : Dose Limiting ToxicitiesTime frame: Up to 21 or 28 days
  3. Phase 2: Overall Response RateTime frame: Approximately 24 months

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.